Yabing Guo
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Liver physiology and pathology 2
-
- Hepatitis B Virus Studies 6
- Liver Disease Diagnosis and Treatment 3
-
- Cancer Immunotherapy and Biomarkers 3
- Pancreatic and Hepatic Oncology Research 2
-
- Cancer Mechanisms and Therapy 2
-
- Cancer Genomics and Diagnostics 3
- Co-authors
- Yuxian BaiZhiqiang MengDonatella MarinoRichard S. FinnFrédéric BoisserieArndt VogelShukui QinTaroh Satoh
- Cited by
- HepatologyEpidemiologyOncology
- Journals
- Journal of Clinical Oncology (7 papers)Journal of Hepatology (1 paper)Experimental Cell Research (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Yabing Guo
14 papers receiving 266 citations
Hit Papers
Peers
Comparison fields: 5 of 46
- Hepatology 179
- Epidemiology 114
- Oncology 87
- Pathology and Forensic Medicine 36
- Cancer Research 26
Countries citing papers authored by Yabing Guo
This map shows the geographic impact of Yabing Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yabing Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yabing Guo more than expected).
Fields of papers citing papers by Yabing Guo
This network shows the impact of papers produced by Yabing Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yabing Guo. The network helps show where Yabing Guo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yabing Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 16 | |
| 3 | 2023 | 3 | |
| 4 | 2023 | 17 | |
| 5 | Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinomabreakdown → | 2023 | 136 |
| 6 | 2023 | 9 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 7 | |
| 9 | 2022 | 1 | |
| 10 | 2022 | 3 | |
| 11 | 2021 | 12 | |
| 12 | 2020 | 48 | |
| 13 | Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. | 2015 | 5 |
| 14 | [Factors influencing the success rate and stability of transient elastography for liver fibrosis evaluation]. | 2008 | 4 |
| 15 | 2007 | 8 |
About Yabing Guo
Yabing Guo is a scholar working on Hepatology, Cancer Research and Oncology, having authored 15 papers that have together received 270 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Hepatitis B Virus Studies (6 papers), Liver Disease Diagnosis and Treatment (3 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Pancreatic and Hepatic Oncology Research (2 papers), Cancer Mechanisms and Therapy (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Hepatology (179 citations), Epidemiology (114 citations) and Oncology (87 citations). Yabing Guo has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Yuxian Bai, Zhiqiang Meng, Donatella Marino, Richard S. Finn, Frédéric Boisserie, Arndt Vogel, Shukui Qin, Taroh Satoh, Andrew X. Zhu and Eric Assénat. Their work appears in journals such as Journal of Clinical Oncology, Journal of Hepatology and Experimental Cell Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.